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Abstract
Background: The complexity of the human plasma proteome represents a substantial challenge for biomarker discovery.
Proteomic analysis of genetically engineered mouse models of cancer and isolated cancer cells and cell lines provide
alternative methods for identification of potential cancer markers that would be detectable in human blood using sensitive
assays. The goal of this work is to evaluate the utility of an integrative strategy using these two approaches for biomarker
discovery.
Methodology/Principal Findings: We investigated a strategy that combined quantitative plasma proteomics of an ovarian
cancer mouse model with analysis of proteins secreted or shed by human ovarian cancer cells. Of 106 plasma proteins
identified with increased levels in tumor bearing mice, 58 were also secreted or shed from ovarian cancer cells. The
remainder consisted primarily of host-response proteins. Of 25 proteins identified in the study that were assayed, 8 mostly
secreted proteins common to mouse plasma and human cancer cells were significantly upregulated in a set of plasmas from
ovarian cancer patients. Five of the eight proteins were confirmed to be upregulated in a second independent set of ovarian
cancer plasmas, including in early stage disease.
Conclusions/Significance: Integrated proteomic analysis of cancer mouse models and human cancer cell populations
provides an effective approach to identify potential circulating protein biomarkers.
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Introduction
Proteins detectable in serum and plasma are commonly relied
upon to monitor ovarian, pancreatic, and colon cancer response to
therapy and disease recurrence through the measurement of
CA125, CA19.9, and CEA respectively. In addition, the screening
and monitoring of prostate cancer currently relies in part on
measurements of PSA levels in blood [1–3]. The development of
effective strategies for identification of circulating protein markers
that complement current markers would be beneficial [4]. A
number of recent ovarian cancer studies have utilized proteomics
to identify proteins in ovarian cancer cells, tissues, and fluids [5–9].
Such studies suggest hundreds of potential candidates on account
of overexpression, but do not give an indication as to whether
increased blood levels of the candidate proteins may occur in
cancer subjects. The identification of novel circulating protein
markers through plasma profiling represents a substantial
challenge. Although plasma is one of the most accessible biological
materials it contains vast assemblies of proteins and complexes and
exhibits considerable heterogeneity between and within subjects
that hinder proteomic analysis of low abundance proteins [10].
Engineered mouse models of cancer characterized by limited
heterogeneity and a favorable tumor to body mass ratio, and
isolated tumor cell populations that may be profiled at substantial
depth present alternative strategies for the identification of
potential cancer markers, notably secreted proteins that may be
subjected to validation in human blood using sensitive assays.
We have developed several mouse models of epithelial ovarian
cancer [11]. These models have been generated using intrabursal
delivery of Adeno-Cre (AdCre) adenovirus via the infundibulum in
genetically engineered mice. This method selectively activates
oncogenes and inactivates tumor suppressors within the ovarian
surface epithelium (OSE), a site of origin for many human ovarian
tumors. We previously relied on the LSL-K-ras
G12D/+ and Pten
loxP/loxP
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develop a mouse model of ovarian cancer [11–13]. A second
model developed in parallel by us and others is based on the
cooperation between the Wnt and Pten pathways (APC
loxP/lox
Pten
loxP/lox genetic combination, herein referred to as Pten/Apc)
[14]. Both models exhibit features of endometrioid ovarian
tumors.
We have recently undertaken proteomic profiling of ovarian
cancer cell populations including cell lines and fresh tumor cells
enriched from ascites fluid, which resulted in the identification of
several thousand proteins and elucidated the repertoire of proteins
expressed on the cell surface and proteins released into the extra-
cellular milieu [15]. Proteome analysis has uncovered shedding of
extra-cellular domains and highly dynamic processes of protein
secretion. Here we have applied an in-depth quantitative
proteomic approach [16–18] to the analysis of plasma protein
changes related to tumor development in a K-ras/Pten ovarian
cancer mouse model to determine their involvement in pathways
and networks and their correspondence to proteins expressed or
released from human ovarian cancer cells. Blinded analysis of
human samples was done to determine which assayed proteins
from the integrated cancer cell and mouse plasma data yielded
statistically significant increases in their levels in ovarian cancer
cases relative to controls. A protein subset representing primarily
secreted proteins from the combined mouse plasma and human
cancer cell proteomic data yielded significant differences in levels
between plasmas from ovarian cancer patients and plasmas from
control subjects.
Results
Quantitative Plasma Protein Changes Observed in an
Ovarian Cancer Mouse Model
A pool of plasma samples from AdenoCre-infected K-ras/Pten
mice (n=5) and a pool from Adeno-empty injected controls (n=5)
were subjected to quantitative proteomic analysis to determine
differences in plasma protein levels. Separate pools of plasma from
cases and controls were subjected to immunodepletion to remove
abundant plasma proteins, followed by differential isotopic
labeling to distinguish cancer cases from controls. The samples
were mixed and then subjected to intact protein fractionation by
ion exchange followed by reverse phase chromatography. Proteins
in the individual collected fractions were enzymatically digested
and subjected to online LC-MS/MS for protein identification and
quantification (Figure 1). A feature of the IPAS platform is that
extensive fractionation allows de-complexing of the samples into
individual fractions to allow identification and quantification of
proteins present in the plasma over 6–7 orders of magnitude
[16,19]. A previous study using this approach has shown that
quantitative analysis of protein changes can be reliably determined
[18]. In this study, some 1,725,000 mass spectra were collected
and analyzed. 1,031 unique proteins were identified with high
confidence (Table S1). 106 proteins were upregulated 1.5-fold or
greater (p-value,0.05) (Table S2). A majority (57%) of the
upregulated proteins contained a signal peptide for secretion,
whereas 17% encompassed in their corresponding gene sequence
a trans-membrane domain. 28% of the upregulated proteins were
previously identified in proteome profiling of mouse liver tissue, a
major source of plasma proteins [20,21]. 9% had no human
ortholog as determined based on the Mouse Genome Database
[22]. In contrast, 36 proteins were downregulated 1.5-fold or
greater (p-value,0.05) (Table S3) including secreted proteins with
8 representing proteins previously identified in mouse liver
tissue.
Comparative Analysis of Tumor Bearing Mouse Plasma
and Human Ovarian Tumor Cell Proteomes
We compared the mouse plasma data with data from an
extensive proteomic study of three human ovarian cancer cell lines
(OVCAR3, CAOV3, and ES2) and of tumor cells from ascites
fluid obtained from an ovarian cancer patient [15]. The cell lines
consisted of two poorly differentiated serous adenocarcinomas
(OVCAR3, CAOV3) and one clear cell carcinoma (ES2). The
ascites derived tumor cells were collected from a patient with
serous ovarian cancer. Cells were isotopically labeled in culture
using SILAC [23] to allow ascertainment of the cellular origin of
proteins identified in media. By comparing the upregulated mouse
plasma proteins with the list of proteins enriched in the surface or
secreted cellular compartments from human ovarian cancer cells
(Table S2), 55% (58/106) of upregulated proteins in mouse plasma
were found to be released from ovarian cancer cells through
secretion or shedding or enriched in the ovarian cancer cell surface
compartment. Previously described candidate markers for ovarian
cancer identified in both the mouse plasma and ovarian cancer
cells (Table S4), included WFDC2 (HE4), IGFBP2, and LCN2.
The balance of proteins not identified in ovarian cancer cell
analyses consisted primarily of inflammatory and immune
response related proteins. Interestingly, although the K-ras/Pten
model has features of endometrioid ovarian cancer, the data
suggested that upregulated secreted proteins identified in mouse
plasma with tumor development were more broadly representative
of other ovarian cancer histological subtypes, since the human cell
lines and ascites derived tumor cells resulted from papillary
adenocarcinoma, clear cell and serous subtypes respectively
[24,25].
In addition to the quantitative cancer-to-control ratios for
proteins presented, several proteins had labeled peptides only
detected with the heavy form of acrylamide, representing ‘‘cancer-
only’’ peptides. Of the 106 proteins up-regulated in mouse plasma
IPAS, 33 proteins had additional cancer-only peptides identified
(Table S2), further corroborating their up-regulated status.
Additionally, seven proteins: Cacna1c, Vcl, Fcgbp, Mmp19, Lyz2,
Eef1a1, and Gapdhs had cancer-only peptides (Table S2). Vcl acts
as a linking protein in focal adhesion and has been studied within
the context of cancer [26]. Mmp19, part of the metalloproteinase
family implicated in cancer, has been reported to induce epithelial
cell migration, playing an important role in the early stage of cancer
[27]. Members of the Eef1a family have been reported as putative
oncogenes overexpressed in ovarian cancer [28,29].
Biological Functions and Networks among Upregulated
Proteins in Mouse Plasma
Pathway analysis was performed to determine the biological
processes that contribute changes to the plasma proteome with
ovarian tumor development, and explore pathways for the
proteins of interest to understand the processes that they
participate in. We relied on two pathway tools to this effect,
Ingenuity and GeneGo’s MetaCore. Initial pathway analysis of the
list of 106 upregulated proteins using the computational gene
network prediction tool, Ingenuity Pathways Analysis, categorized
the proteins into biological functions. Thirty proteins were
associated with inflammation (p=1.30610
26). Cancer was
identified as a significant disease process (p=3.71610
25)i n
relation to all proteins identified, being represented by 52 relevant
proteins from this list. Interestingly, genes for 11 proteins were
associated as a group with ovarian cancer (p=1.41610
23) (CFH,
CLU, IFI30, IGFBP2, IGFBP4, LCN2, MMP2, POSTN, TFF3,
TNFRSF9, HE4 (WFDC2). HE4, a known candidate marker for
Ovarian Cancer Proteomics
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murine plasma data set. Some proteins from this list have also
been identified in tumor studies as clinical outcome predictors
(NOV, CLU TNC, POSTN, IGFBP2, LCN2) or mediators of
resistance to chemotherapy (CLU, FBLN1, THBS, STIP1,
PTGES3, IGFBP4, ATOX1) [32–45].
58 of the 106 upregulated proteins in the mouse plasma analysis
were found to be also enriched in the surface or secreted sub-
Figure 1. Study Design. A schematic of the workflow used in this study. Pools of control and cancer plasma from the K-ras/Pten mouse model
were first immunodepleted to remove abundant proteins and then labeled with D0- and D3- acrylamide isotopes to distinguish cancer from control.
The pools were mixed and subjected to extensive intact protein fractionation by anion exchange, followed by reverse phase chromatography. After
tryptic digestion, samples were subjected to high resolution mass spectrometry and shotgun LC-MS/MS analysis for protein identification and
quantitation. Following statistical analysis and data mining, upregulated proteins in murine plasma were compared to human ascites derived tumor
cells/cancer cell line data. In addition, pathway analysis was used to determine significant biological pathways and processes. The expression of
relevant upregulated proteins was further validated in mouse and human tumors and plasma.
doi:10.1371/journal.pone.0007916.g001
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these 58 proteins identified four significant networks using
Ingenuity (Figure 2 and Figure S1) and five networks with
MetaCore’s workflow (Figure S2). The most prevalent processes
highlighted in the Ingenuity networks included tumor growth, cell
proliferation and apoptosis, regulation of tumor microenviron-
ment, angiogenesis, cellular migration, invasion, and metastasis
(Table S5). An additional assessment using MetaCore’s enrich-
ment tools across GeneGo ontologies and Gene Ontology (Figure
S2, Figure S3, Table S6) confirmed cell adhesion, proliferation,
development and extracellular matrix remodeling as significant
represented processes. The top two networks generated by
Ingenuity underscore the importance of TGFb-mediated regula-
tion of cell proliferation, metabolism and cytoskeletal remodeling
(Figure 2, Table S5), complementing the MetaCore enrichment
results (Figure S3). In addition to TGFb, other central nodes (with
both Ingenuity and MetaCore) include MMP2, p38MAPK, NFkB,
and RAS, all known to be important in ovarian cancer [46,47].
Pathway analysis of the 48 proteins that were found to be
upregulated in mouse plasma with tumor development, but not
identified as secreted or surface membrane proteins in ovarian
cancer cells yielded three significant networks with Ingenuity
(Figure S4, Table S5). The list included putative inflammatory
proteins such as haptoglobin (HP), S100A8, and CCL8. The
categorization of upregulated proteins in the plasma based on
enrichment in ovarian cancer cells sub-fractions provided a means
for assessing which upregulated proteins in plasma were more
likely derived from cancer cells, and which proteins were more
likely related to host-response.
Immunoblot Analysis of Mouse and Human Specimens
A set of proteins identified in ovarian cancer cells and found to
be upregulated in plasma from tumor bearing mice, TIMP1,
LCN2, IGFBP2, PFN1, SPARC, EEF1B2, CLU, and FBLN2,
were selected for immunoblot analysis using tumor tissue collected
from mouse models, conditioned media from human ovarian
cancer cell lines, and primary ovarian tumors from human
subjects. Increased protein levels for Timp1, Lcn2, Igfbp2, Pfn1,
and Sparc were observed in ovarian tumor tissues isolated from K-
ras/Pten (Figure 3A) and Pten/Apc (Figure 3B) ovarian cancer
mouse models compared to control tissue lysates. Similarly,
enrichment in TIMP1, LCN2, IGFBP2, PFN1, SPARC, EEF1B2,
CLU, and FBLN2 was observed in conditioned media (CM)
collected from ovarian cancer cell lines derived from serous
adenocarcinomas (OVCAR-3, SKOV3, CaOV3, OVCAR-5,
OVCAR-8), endometrioid carcinoma (TOV112D), clear cell
carcinoma (ES-2, IGROV1) compared to conditioned media
derived from human ovarian surface epithelium (HOSE,
Figure 3C). In addition, expression levels of TIMP1, LCN2,
PFN1, IGFBP2, SPARC, EEF1B2, CLU, and FBLN2 were
elevated in ovarian tumor lysates compared to control tissue
freshly collected from patients undergoing surgery (Figure 3D).
ELISA Assays Using Mouse and Human Plasmas
We further tested a subset of proteins found by mass
spectrometry to be upregulated in plasma from tumor bearing
mice, for their levels in human and murine plasma. We also
compared performance of proteins found to be secreted by ovarian
cancer cells but were either not identified in mouse plasma or not
found to be elevated in plasma from tumor bearing mice. 25
proteins were chosen based on availability of ELISA assays. For
mouse assays, we assessed levels of Timp1 and Lcn2 in biological
fluids and plasmas from tumor bearing mice (Stage I/II, n=6;
Stage III/IV, n=5; controls, n=18). Timp1 levels in Stage I/II
and Stage III/IV samples were increased 5.9-fold (p,0.0001) and
9.5-fold (p,0.0001) compared to controls, respectively (Figure 4A).
Similar findings were observed for Lcn2 (Figure 4B). We further
examined whether Timp1 and Lcn2 were enriched in fluid
extracted from late stage ovarian tumors and in peritoneal ascites
given the proximity of these fluids to ovarian cancer cells and the
Figure 2. Networks. Top two networks (A, B) assigned by Ingenuity
Pathway Analysis for upregulated proteins in the mouse plasma that
were also enriched in the cancer cell line data. Central nodes include
TGFb, PI3K, MMP-2, Ras, and MAPK. Proteins colored in red represent
upregulated proteins and non-colored proteins are those assigned by
Ingenuity databases as possible intermediate interactions as based on
the Ingenuity database. Solid lines indicate direct relationships (two
molecules make physical contact) and dotted lines indicate indirect
relationships (does not require physical contact). The scores for A) and
B) are 51 and 24 respectively.
doi:10.1371/journal.pone.0007916.g002
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than 400-fold and 250-fold in ovarian tumor fluid and peritoneal
ascites compared to murine plasma, respectively (Figure 4C).
Likewise, Lcn2 had a similar pattern with a 79- and 19-fold
increased levels in ovarian tumor fluid and peritoneal ascites,
respectively (Figure 4D), consistent with their active secretion into
surrounding fluids by tumor cells.
The 25 proteins chosen for assays in human plasmas were
either: 1) up-regulated in mouse plasma, 2) expressed by ovarian
cancer cells, or 3) both up-regulated in mouse plasma and
expressed by ovarian cancer cells. The initial set of human
plasmas, henceforth referred to as Set 1, consisted of plasma
samples from 13 women with epithelial ovarian cancer (n=3 early
stage, n=10 late stage) and 56 healthy women. All samples in Set
1 were collected in the clinic, under non-surgical conditions (Table
S7). Assay results from Set 1 are summarized in Table S2, together
with the mouse plasma and cell line data used to choose the
proteins for testing. The levels of 8 of the 25 proteins, GRN,
IGFBP2, THBS1, RARRES2, TIMP1, PPBP, CD14, and
NRCAM, were found to be statistically significantly (p,0.05)
elevated in newly diagnosed subjects with ovarian cancer
compared to controls (Table 1, Figure 5).
Interestingly, 5 of the 8 proteins found up-regulated in Set 1
(GRN, IGFBP2, THBS1, RARRES2, and TIMP1) were secreted
proteins from the intersection of mouse plasma and cancer cell
data. PPBP was a secreted protein found up-regulated in the
mouse plasma, but not discovered in the ovarian cancer cell lines,
while CD14 and NRCAM were cell surface proteins from the
ovarian cancer cell lines, and were not quantified in mouse
plasma.
The 8 proteins that showed statistically significant increased
levels in Set 1 assays were further tested in an additional set of
human plasma samples, henceforth referred to as Set 2. Set 2
consisted of plasma samples from 55 women with epithelial
ovarian cancer (n=31 early stage, n=23 late stage, and n=1
stage unknown) and 39 controls undergoing surgery. All samples in
Set 2 were collected in the operating room under surgical
conditions (Table S7). Of the 8 proteins found significant in Set 1,
5 proteins (GRN, IGFBP2, RARRES2, TIMP1, and CD14) were
confirmed to be up-regulated in Set 2 (Table 1, Figure 5). Notably
all 5 of the proteins were statistically significantly elevated in the
early stage samples.
Of the 25 proteins that were assayed, ten had concordant
findings in mouse plasma and cell line data. Interestingly, five
proteins that were present at the intersection of candidates from
mouse plasma and cell population data (GRN, IGFBP2, THBS1,
RARRES2, and TIMP1), were found to be significantly
upregulated in Set 1 and four of the five proteins were confirmed
in Set 2, with THBS1 as the exception.
Specimen collection conditions can affect the levels of
circulating proteins. For instance, patients who have blood drawn
at the time of surgery may have increased levels of certain proteins
as a result of stress [48]. Using a previously described method [48],
we evaluated whether protein levels differed between case and
control groups after adjusting for conditions of blood collection. In
the samples used for assays, seven ovarian cancer patients had
blood draws at two time points: prior to surgery, and at the time of
surgery. The protein levels at both time points for each patient are
shown in Figure S5. Regression analyses were performed using
Generalized Estimating Equations (GEE) methods [48] to account
for the correlation in the protein levels of the 7 women with two
blood collections, and give p-values that are unbiased by the
multiple blood draws from the same women (Table S8). After
adjusting for conditions of blood draw, the five proteins previously
found significant in Set 1 and Set 2 logistic regression analysis,
were also found significant in the GEE model for the case versus
healthy control comparison. For a secondary GEE model, the
coefficient for blood draw conditions were fixed from the first GEE
analysis to avoid bias from refitting. The second analysis was
restricted to specimens collected at surgery and all 5 proteins
found significant in the first analysis were significant in the case vs.
non-case, early case vs. non-case, and late case vs. non-case
comparison. These results support the findings from the logistic
regression and show that IGFBP2, TIMP1, RARRES2, CD14,
and GRN are elevated in all cases compared to control and
importantly in early cases compared to controls.
GRN has been described as a putative novel growth factor for
ovarian cancer, and was found to be highly secreted by ovarian
cancer cells [49]. Increased levels of GRN and RARRES2 in
Figure 3. Validation of key tumor markers by western blotting.
Protein levels of TIMP1, LCN2, PFN1, IGFBP2, SPARC, EEF1B2 and CLU
were determined from the following: (A) normal ovarian tissue (N) and
ovarian tumors (T) isolated from the K-ras/Pten, or (B) Pten/Apc mouse
model of ovarian cancer, (C) conditioned media (CM) from normal
human surface epithelium cells lines (HOSE) and ovarian cancer cell
lines and (D) human primary tissues (HPT): normal ovarian tissue (N) and
ovarian tumors (T). For mouse preparations, tissue lysates were
prepared from normal ovaries and tumors taken from the same animal
(a–d) along with four-five tumors from separate animals (e–i). For
human primary tumor (HPT) samples, tissue lysates were prepared from
4 tumor samples paired with their respective normal tissue from the
same patient and 3 lone tumor samples, in which no normal samples
were available. Patient samples are as follows: patient #14 had
independent bilateral serous borderline tumors in the left (TL) and right
ovary (TR), tumors #3, #7, and #15 are papillary serous carcinomas,
tumor #12 is an epithelial borderline tumor of the Mu ¨llerian-type, with
endocervical mucinous and serous differentiation, tumor #13 is clear
cell carcinoma, and tumor #16 is endometrioid adenocarcinoma.
doi:10.1371/journal.pone.0007916.g003
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stage cases are a novel findings in this study. CD14, and IGFBP2
have been previously assayed in serum from ovarian cancer
patients [37,50,51]. They were significantly elevated in this study
in mouse plasma and enriched in the secreted protein fraction of
ovarian cancer cell lines. A finding of interest in our study is the
occurrence of increased levels of IGFBP2 and CD14 in early stage
disease. TIMP1 performed also showed increased levels in both
early and late stage cases. Cell line data indicated that TIMP1 was
released from ovarian cancer cells at nanograms per million
cancer cells per hour [18] which would account for increased
levels in human ovarian cancer patient samples.
Discussion
There is currently a limited understanding of the changes in
plasma proteins that occur with the development of ovarian
tumors and for most tumor types in general [52,53]. The discovery
of novel plasma markers has represented a substantial challenge,
particularly for markers that are applicable to early stage disease.
Analysis of high-dimensional genomic, transcriptomic or proteo-
mic data allows for affected pathways, networks and signaling
nodes to be explored [53,54]. The present study provides evidence
for the utility of integrating data from in-depth quantitative
proteome analysis of mouse models of cancer with data from
human cancer cells for biomarker identification. Here we used a
mouse model of epithelial ovarian cancer in combination with the
IPAS proteomic platform to allow us to reliably assess and quantify
changes encompassing low abundance proteins in mouse plasma
with tumor development [53]. Integration with data from human
ovarian cancer cell lines provided a means for assessing which
upregulated proteins were expressed in cancer cells. Additionally
signaling nodes that contributed upregulated proteins in plasma
were determined. As a result, proteins that likely resulted from
inflammatory and immune response changes were distinguished
from proteins that more likely resulted from secretion by tumor
cells or from tumorigenic processes. Changes in tumor microen-
vironment and ECM are associated with autocrine regulation.
ECM proteins have been previously identified as ovarian cancer
metastasis signature genes [55,56]. Changes in the cytoskeleton
were observed including cytoskeletal-mediated migration, adhe-
sion, and invasion. Lastly, cellular proliferation changes were
observed and incorporated cell apoptosis. Several central signaling
nodes were identified in this study including TGFb, MMP2 and
NFkB signaling. TGFb, signaling in particular is central to a
multitude of processes, including cell proliferation and apoptosis,
ECM remodeling, cell migration, adhesion, invasion and metas-
tasis, angiogenesis, and inflammation and immune surveillance
[57,58]. The TGFb family is an active target for cancer prevention
and therapy [57,58]. Interestingly, TGFb is known to have both
tumor suppressor and pro-oncongenic effects in various cancers
including ovarian [59]. TGFb also plays a role in epithelial stem
cell niche homeostasis [60], and deletion of TGFb receptor
induces a highly proliferative and invasive environment [61].
Tumbar et al. also determined that the loss of TGFb receptors in
combination with oncogenic Ras enhanced tumorigenicity. This
hypothesis is also supported by the generated networks in our
pathway analysis (Figure 2B), in which NFkB (presumably under
the control of TGFb) is assigned to elicit Ras, PI3K, and MAPK
signaling towards actin-mediated responses driving cellular
Figure 4. Plasma levels of mouse TIMP1 and LCN2 in cancer cases versus controls. TIMP1 and LCN2 levels in murine plasma at various
stages of tumor progression were determined by ELISA as described in the Materials and Methods (A, B). Also shown are TIMP1 (C) and LCN2 (D)
levels in murine ovarian tumor fluid and peritoneal ascites as compared to plasma. Statistical significance was determined using a two-tailed
Student’s t-test *p,0.05, **p,0.01, and *** p,0.0001 compared to controls.
doi:10.1371/journal.pone.0007916.g004
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signaling is reminiscent of its effects on embryonic stem cell
pluripotency and embryonic tissue development, including the
ovary [62–64]. Consistent with this hypothesis, additional
networks illustrated by pathway analysis (Figure S1) for the late
stage proteome highlight Notch and Dkk3, known stem cell
effectors [65,66]. It is therefore not surprising that this effector is
dominant in the plasma and cancer cell line data, supporting the
current role of TGFb as it elicits a variety of responses relevant to
cancer processes (proliferation, apotosis, inflammation, angiogen-
esis, autorcrine-regulation of tumor microenvironment/ECM and
adhesion, invasion, and metastasis).
In a search for potential ovarian cancer biomarkers, we
performed a novel integrative analysis by comparing mouse
plasma proteome data with human cell line and ascites derived
tumor cell data. By using a mouse model to identify proteins of
interest, extraneous sources of heterogeneity unrelated to disease
were minimized. A large number of proteins common to plasma
from tumor bearing cell lines and human ovarian cancer cells were
found to be involved in cellular/tissue remodeling and cell-cell
contact/communication that dictate alterations in ECM processes
and facilitate cell migration, local tumor growth, and tumor
metastasis. In this integrated analysis the subset of proteins that
were most successfully validated in human ovarian cancer sera
represented proteins found to be upregulated in plasma from
tumor bearing mice and found to be secreted in human ovarian
cancer cells. A lower percentage of proteins found to be
upregulated in the mouse model or were found only in ovarian
cancer cell data, yielded validated candidate markers in our set of
human plasmas.
We chose the K-ras+/Pten(-) ovarian cancer model initially
because of its histopathological representation of a subtype of
ovarian cancer. However the finding of elevated levels in mouse
plasma of proteins previously associated more broadly with
ovarian cancer, led us to investigate the merits of integrating
mouse plasma proteomic findings from this model with proteomic
findings from ovarian cancer cells. The candidate proteins chosen
for assays were tested in samples from human patients with a
variety of ovarian cancer histologies. It is likely that these potential
markers are broadly applicable to ovarian cancer and not confined
to a specific histology or genetic subtype.
In this study, five proteins that exhibited significant differences
in plasmas from subjects with ovarian cancer relative to controls
were comprised predominantly of secreted proteins at the
Figure 5. Plasma levels of human GRN, IGFBP2, THBS1, RARRES2, TIMP1, PPBP, CD14, and NRCAM in Set 1 and Set 2 samples. In Set
1, protein levels in cancer patients were compared to levels in the healthy controls, with all samples collected in the clinic under non-surgical
conditions. In Set 2, protein levels in cancer patients were compared to controls with all samples collected in the operating room under surgical
conditions. Logistic regression analysis was used to determine statistical significance of changes in protein levels between case and control groups.
For Set 2, the p-values for the early and late stages were calculated if the p-value was significant in the entire Set 2 (all cases). *p,0.05, **p,0.01, and
***p,0.0001 for cases compared to controls. Marker levels were normalized to give healthy controls a mean of 0 and a standard deviation of 1. The y-
axes represent the standardized marker levels.
doi:10.1371/journal.pone.0007916.g005
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PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7916intersection of upregulated proteins in mouse plasma and secreted
proteins in proteomic data from ovarian cancer cell populations.
Further validation studies with these proteins as well as with
additional candidates for which specialized assays are currently not
available would be warranted. Integration of mouse model and cell
line data as implemented in this study provides an innovative
strategy that would be applicable to other cancer types for the
discovery of circulating biomarkers.
Materials and Methods
Reagents and Antibodies
Anti-human and anti-mouse rat polyclonal LCN2 (1:500),
mouse monoclonal anti-human Clu (1:500), and goat polyclonal
anti-mouse Timp1 (1:200) were purchased from R&D Systems
(Minneapolis, MN US). Rabbit polyclonal anti-mouse/human
EEF1B2 was purchased from Protein Tech (Chicago, Il US) rabbit
polyclonal anti-mouse/human PFN (1:2000) was purchased from
Cell Signaling (Danvers, MA) and anti-mouse/human IGFBP2
(1:500) was purchased from Upstate Biotechnology (Lake Placid,
NY). Anti-human FBLN2 (1:200), anti-human/mouse SPARC
(1:250), and anti-mouse/human TIMP1 (1:250) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA US). Anti-rat-
horseradish peroxidase (HRP) conjugated secondary antibody
(1:2000) was purchased from Pierce Biotechnology Inc (Rockford,
IL) and anti-mouse/rabbit/goat-HRP conjugated secondary
antibodies were purchased from Vector Laboratories Inc (Burlin-
game, CA).
Cell Culture
Human ovarian cancer cell lines OVCAR3, OVCAR5,
OVCAR8, IGROV1, SKOV3 and TOV112D were maintained
as 70% confluent monolayers in RPMI containing 10% FBS and
1% penicillin/streptomycin cocktail. Normal human ovarian
surface epithelial lines (HOSE) and CaOV3 and ES-2 cancer cell
lines were maintained in DMEM containing 10% FBS and 1%
penicillin/streptomycin cocktail.
Collection of Mouse Plasma
All animal studies were done in accordance with institutional
guidelines and approved by the Harvard Medical School Animal
CareandUse Committee. Generation of LSL-K-ras
G12D/+Pten
loxP/loxP
mice and adenoviral induction of ovarian tumors was accomplished
as previously described [11]. Control mice were littermates that
underwent the same surgical procedure but were injected with
Adeno-empty virus instead of Adeno-Cre. Plasma was collected at
a 10 week time point following Adeno-Cre (cancer cases n=5) or
Adeno-empty injection (controls n=5). Cancer cases (10 weeks
post-injection) had large ovarian tumors that had metastasized to
pelvic or peritoneal locations. To collect plasma, mice were
euthanized and blood was collected by cardiac puncture using a
22-gauge needle and 1 ml syringe. The blood was placed into a
K3EDTA coated 1.5 ml microcentrifuge tube using a needless-
syringe. After cardiac puncture, mice were surgically and
pathologically examined to confirm the presence of ovarian
tumors and metastases. Tumor volumes were calculated using the
following formula (length6width6height)/2 according to pub-
lished literature [67].
The collected murine blood was processed as follows: K3EDTA
tubes containing the blood were centrifuged at room temperature
for 10 minutes at 1500 rpm. The top layer of plasma was extracted
from the separated blood mixture using a pipet, aliquoted, and
frozen at 280uC. Plasma from 5 mice with cancer and 5 control
mice were pooled for further analysis. 200 ml from each individual
mouse was used to generate a pooled sample volume of 1 ml.
Plasma Sample Depletion and Isotopic Labeling
Separate pools of cancer cases and controls were immunode-
pleted of albumin, IgG, and transferrin using a Ms-3 column
(4.66250 mm, Aglient, Wilmington, DE). The column was
equilibrated with buffer A for 13 min at a rate of 0.5 ml/min.
Pooled sera were filtrated through a 0.22 mm syringe filter and
injected 75 ml at a time. Flow through fractions were collected for
10 minutes at a rate of 0.5 ml/min Buffer A. These fractions were
combined and stored at 280uC until use. Material bound to the
column was recovered by elution with buffer B for 8 min at a rate
of 1 ml/min. Centricon YM-3 columns (Millipore) were used to
concentrate the immunodepleted samples. These samples were
then re-diluted in 8 M urea, 0.5 octyl-beta-d-glucopyranoside
(Roche) and 30 mM Tris pH 8.5. Before labeling, each pooled
sample was reduced with dithiothreitol (DTT) in 50 ml 2M Tris-
HCl, pH 8.5 (0.66 mg DDT/mg protein). Next, isotopic labeling
of intact proteins was accomplished by labeling the cysteine
residues with acrylamide [68]. Control samples received the light
acrylamide isotope (D0 acrylamide, Fluka), while cancer samples
were labeled with the heavy 2,3,39-D3-acrylamide isotope (D3
acrylamide, Cambridge Isotope Laboratories). Labeling was
performed for 1 hour at room temperature. Pooled samples were
either labeled with 7.1 mg of light acrylamide or 7.4 mg of heavy
acrylamide per milligram of protein that had been diluted in a
small volume of 2M Tris-HCl, pH 8.5.
Protein Fractionation and Analysis by Mass Spectrometry
Following isotopic labeling, the cancer cases and control pools
were mixed. The sample was fractionated identically in two
dimensions: first by anion exchange (AEX) and second by reverse
phase (RP). Fractionation was carried out as described previously
[19], with a few modifications. Briefly, the mixed, labeled samples
were diluted to 10 ml with 20 mM Tris in 6% isopropanol, 4 M
Urea, pH 8.5, and injected immediately into a Mono-Q 10/100
column (Amersham Biosciences). The buffer system for the first
dimensional fractionation scheme was solvent A: 20 mM Tris in
6% isopropanol, 4 M Urea pH 8.5 and solvent B: 20 mM Tris in
6% isopropanol, 4 M Urea, 1 M NaCl pH 8.5. The separation
gradient was performed at a 4.0 ml/min flow rate as follows: 0 to
35% gradient of solvent B for 44 min, 35 to 50% gradient of
solvent B for 3 min, 50 to 100% solvent B in 5 min, and a hold in
solvent B at 100% for another 5 min. 65 fractions were collected
and further pooled into 9 fractions (fractions 1–13, 14–24, 25–27,
28–30, 31–36, 37–39, 40–42, 43–45, and 46–65). These 9 pooled
fractions were then separated by reverse phase fractionation on a
Poros R2 column (4.6650 mm, Applied Biosystems). Samples
were fractionated in a TFA/acetonitrile buffer system as follows:
Solvent A, composed of 95% H20, 5% acetonitrile, and 0.1% TFA
and Solvent B, composed of 90% acetonitrile, 10% H20, and
0.1% TFA. The flow rate was set at 2.7 ml/min and the following
gradient was used: a desalting step of 5% Solvent B until the
absorbance reached base line, 5 to 50% gradient of solvent B for
18 min, 50 to 80% solvent B for 7 min, and 80 to 95% solvent B
in 2 min. Sixty-three 1.2 ml fractions were collected, thus a total of
567 fractions were generated from the entire two-dimensional
fractionation. RP fractions from each of the 9 AEX fractions were
pooled into 16 fractions (RP fractions).
In solution digestion with trypsin was performed on lyophilized
aliquots of a total 144 pools. The samples were then subjected to
shotgun LC-MS/MS analysis on a LTQ-FT (ThermoFisher
Scientific) mass spectrometer equipped with a nano-LC system
Ovarian Cancer Proteomics
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(Picofrit 75 um ID, New Objective), packed in house with Magic
C18 packing material (Michrom)). A 90-minute linear gradient
was then applied from 5 to 40% acetonitrile in 0.1% formic acid at
300 nL/min. Spectra were acquired in data dependent mode with
a MS1 m/z range of 400 to 1800, followed by selection of the 5
most abundant doubly or triply protonated ions in each MS1
spectrum for MS/MS analysis. The mass spectrometer parameters
were as follows: capillary voltage of 2.1 kV, capillary temperature
200 degrees C, 100,000 resolution, and FT target value of
2,000,000.
Protein Identification and Quantification
Data analysis was performed using the Computational Proteo-
mics Analysis System [69]. Searches were performed using
cysteine alkylation modification with the light form of acrylamide
as a fixed modification and the heavy form of acrylamide
(+3.01884) as a variable modification. Spectra were searched
using X!Tandem [70] configured with the comet score module
plug-in [71] against the mouse IPI database [72] version 3.29. A
search for tryptic peptides was performed with a semitryptic
refinement option where a second round of searching is performed
for semitryptic peptides from proteins identified in the first round
of searching.
Quantitative ratios were obtained for peptides containing
cysteine residues labeled with heavy and light acrylamide isotopes.
Quantitative information was extracted from acrylamide labeled
peptides using an in-house script (Q3); this allowed us to obtain the
relative quantification from MS1 spectra for each pair of peptides
identified by MS/MS that contains cysteine residues [68].
Calculation of ratios between cancer and normal were fraction-
centric (per LC-MS/MS run). All identified peptide measured
acrylamide ratios were processed such that multiple measurements
for a given peptide in one individual fraction were log2 averaged,
resulting in a dataset containing one ratio per peptide per each
individual fraction. A global normalization factor was then
computed as the mode of the peptide ratio histogram. All peptide
ratios for a specific protein present in a particular fraction were
then normalized and log-averaged to obtain the local relative
protein ratio. Statistical significance of protein quantitation was
assigned by two methods as described below.
Proteomic Data Analysis
Data was interrogated using Ingenuity Pathways Analysis
(Ingenuity SystemsH, www.ingenuity.com) and MetaCore from
GeneGo Inc (www.genego.com). A dataset containing IPI
accession numbers and the corresponding cancer-to-control ratios
was uploaded into each application where all 1031 proteins
identified in the IPAS experiment were used as a reference set.
Each accession number was mapped to its corresponding gene
object in the Ingenuity’s knowledge base or MetaCore’s manually
curated data base. A fold change cutoff of 1.5 with a p-
value,0.05, was set to identify genes whose expression was
significantly differentially regulated. For analysis with Ingenuity,
these genes, were designated as focus genes and were overlaid onto
a global molecular network developed from information contained
in the Ingenuity knowledge base. Networks of these focus genes
were then algorithmically generated based on their connectivity. A
score is generated for each network based on the fit between the
focus genes and each network. The score is the –log(p-value)
calculated based on a hypergeometric distribution with the right-
tailed Fisher’s Exact Test. For analysis with MetaCore, the gene
list of proteins found to be up-regulated in the mouse plasma and
secreted/shed in mouse and human cancer cell lines (total of 58
genes) was submitted to an enrichment and network workflow.
Enrichment analysis was conducted across three GeneGo curated
ontologies along with Gene Ontology [73] to provide a
quantitative analysis of the most relevant biological functions
represented by the data. Networks and the statistics for each, were
generated using the analyze network algorithm, one of the nine
network building algorithms in MetaCore.
PeptideProphet [74], an empirical statistical modeling program,
was used to estimate the accuracy of peptide identifications.
Factors determined by the search algorithm were weighted to
assign a single number for each peptide identification that can be
then compared to other peptide identifications. ProteinProphet
[75] a program that applies a statistical model to infer protein
groups from peptide identifications and validates these groups with
a probability assignment, was also utilized. A protein group may
contain one or more protein sequence, with each sequence being
indistinguishable based on the identified peptides. Proteins with a
ProteinProphet score corresponding to 5% error rate (,3.5% false
discovery rate as determined by ProteinProphet) were retained. In
this study, for each protein group, henceforth referred to as
‘‘protein’’, a representative gene symbol was chosen.
Immunoblot Analysis
The expression pattern of key proteins from the IPAS analysis
was analyzed in conditioned media (CM) of human ovarian cancer
cell lines and human primary ovarian tumors (HPT) freshly
collected from patients undergoing surgery. Human sample
collection was approved by the Partners HealthCare Human
Research Committee (Institutional Review Board), Harvard
Medical School. In addition, western blot analysis was performed
on ovarian tumors collected from two mouse models of ovarian
cancer: K-ras/Pten and Pten/Apc.
Tissue homogenates were made with RIPA buffer (50 mM Tris-
HCL, 150 mM NaCl, 1% NP-40, 0.5 C24H39NaO4, 0.1% SDS,
pH 7.4) containing freshly added protease inhibitor cocktail Set I
and II (Calbiochem, US) and Complete Mini Inhibitors (Roche,
Indianapolis, US). Conditioned media (CM) was first concentrated
for 30 min at 3000 rpm using Amicon Ulita-5 centrifugal filter
device (Millipore, Billerica US) as described by the manufacturer.
Samples were then sonicated or passed through a 27-gauge needle
and protein concentrations were determined using a Bio-Rad
system (Hercules CA, US). 10–20 mg of mouse primary tissue,
20 mg of HPT, or 40 mg human CM samples were prepared with
RIPA buffer and 1X Laemmli sample buffer and then heated for
5 min at 100uC. Samples were resolved on 8, 12 or 15% SDS-
PAGE gels and transferred to polyvinylidene difluoride membrane
for 2 h. Membranes were subsequently blocked with 5% Milk in
Tris-buffered saline containing 0.1% Tween-20 (20 mM Trisbase,
137 mM NaCl, pH 7.6) and incubated overnight at 4 deg C with
primary antibodies, as specified in the text (for dilutions see
Reagents and Antibodies). Horseradish peroxidase-conjugated
secondary antibodies (1:2000) were applied for 1 hour at room
temperature and detection by chemiluminescence was performed
using SuperSignal West Pico Chemiluminescent Substrate as
specified by the manufacturer (Pierce Biotechnology Inc, Rock-
ford, IL). Equal protein loading was assessed by probing for total
actin protein.
Enzyme-Linked Immunoabsorbant Assays
For validation studies using ELISA, we collected plasma from
infected mice at variousstages of tumor progression and controls. In
addition, we also collected ascites or ovarian tumor fluid extracted
from late stage tumors. Timp1 concentrations in murine plasma
were measured using a Quanitikine-Mouse Timp1 ELISA Kit,
Ovarian Cancer Proteomics
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(R&D Systems, Minneapolis, MN USA). To measure Timp1, we
diluted mouse plasma samples 1:6, while a 1:400 dilution was used
for Lcn2. For data analysis, mice were grouped according to disease
stage: control, Stages I-II (early stage) and Stage III-IV (late stage).
Human plasma samples were collected from women who
consented to participate in a specimen donation protocol
conducted by the Pacific Ovarian Cancer Research Consortium,
which was approved by the Fred Hutchinson Caner Research
Center Institutional Review Board. Each patient provided written
informed consent. 163 samples were obtained in total consisting of:
68 women newly diagnosed with ovarian cancer (55 collected at
the time of surgery, 13 collected in advance of surgery), 56 healthy
controls (collected in the clinic from apparently healthy women
attending regular breast cancer screening exams), and 39 surgical
controls (11 patients undergoing gynecologic surgery for a variety
of conditions but with normal ovarian pathology, and 28 samples
from patients with benign ovarian disease collected at the time of
surgery). The same specimen processing protocol was used for all
samples. Human plasma levels of ADAM17 (1:4), TNFRSF21
(1:20), PI3 (1:10), LGMN (1:25), AXL (1:250), IGFBP2 (1:250),
RARRES2 (1:250), DKK3 (1:300), ALCAM (1:350), HGFR
(1:1000), CD14 (1:2000), XLKD1 (1:2000), VCAM1 (2500),
NrCAM (1:20), CDH1 (50), PPBP (1:1000), IGF1R (1:2) and
NOV (1:20) were evaluated using DuoSets, while plasma
concentrations of TIMP1 (1:100), THBS1 (1:100) and TGFb1
(1:40) were measured using Quantikine kits (all purchased from
R&D Systems, Minneapolis, MN, USA). Plasma levels of vWF
(1:100) (American Diagnostics, Stamford, CT, USA), GRN (1:200)
(Adipogen, Seoul, South Korea), sICAM2 (1:20) (Abcam, Cam-
bridge, MA, USA), and LCN2 (1:500) (BioPorto Diagnostics,
Gentofte, Denmark) were also measured. All assays using human
plasma were done with sample clinical characteristics blinded.
Statistical Analysis
Statistical significance of protein quantification by mass
spectrometry was determined by two methods. Proteins for which
multiple paired MS events of heavy and light acrylamide were
observed, a one-sample t-test was used to calculate a p-value for
the mean ratio of the whole protein across all fractions. Secondly,
the probability for the ratio for each MS event was calculated from
the distribution of ratios in a control-control experiment in which
the same sample was labeled with heavy and light acrylamide. If
the p-value for each individual event was ,0.05, the overall
protein ratio was considered statistically significant.
For ELISA measurements, protein levels were normalized to
eliminate batch-to-batch variation in measurements. Marker levels
werenormalized togive healthycontrolsa meanof0 and a standard
deviation of 1 [76]. Different groups were compared using logistic
regression analysis. In addition, regressions were performed to
evaluate which proteins differed between case and control groups
after adjusting for blood collection conditions using Generalized
Estimating Equations methods. The Bonferroni adjustment was
used to account for multiple testing using a value of 25 for the
number of comparisons (since 25 proteins were assayed).
Data for the mouse plasma experiments has been deposited in
the Mouse Peptide Atlas (www.peptideatlas.org/repository). Sam-
ple accession number PAe000322 [77].
Supporting Information
Figure S1 Additional networks for upregulated in mouse plasma
and enriched in ovarian cancer cell data. The remaining significant
networks for proteins upregulated in mouse plasma and enriched in
cancer cell data assigned by Ingenuity Pathway Analysis are shown.
Proteins colored in red represent proteins from the IPAS list. Non-
colored proteins are those assigned by the Ingenuity database as
possible intermediate interactions. Solid lines indicate direct
relationships (two molecules make physical contact) and dotted
lines indicate indirect relationships (does not require physical
contact). The scores for A) and B) are 51 and 24 respectively.
Found at: doi:10.1371/journal.pone.0007916.s001 (0.38 MB
PDF)
Figure S2 Significant networks for upregulated in mouse plasma
and enriched in ovarian cancer cell data (by Metacore analysis).
Five significant networks for proteins upregulated in mouse plasma
and enriched in cancer cell data assigned by Metacore analysis are
shown. Proteins with a pink dot represent proteins from the IPAS
list. The p-values for each network are: A) 5.73e-24, B) 5.73e-24,
C) 5.73e-24, D) 5.73e-24, E) 5.02e-15.
Found at: doi:10.1371/journal.pone.0007916.s002 (0.75 MB
PDF)
Figure S3 A) Gene Ontology and B) GeneGO processes for the
58 proteins upregulated in mouse plasma and enriched in ovarian
cancer cell data.
Found at: doi:10.1371/journal.pone.0007916.s003 (0.13 MB
PDF)
Figure S4 Significant networks for proteins upregulated in
mouse plasma and not found enriched in ovarian cancer cell data.
The significant networks for proteins upregulated in mouse
plasma, but not enriched in cancer cell data assigned by Inenuity
Pathway Analysis are shown. Proteins colored in red represent
proteins from the IPAS list. Non-colored proteins are those
assigned by the Ingenuity database as possible intermediate
interactions. Solid lines indicate direct relationships (two molecules
make physical contact) and dotted lines indicate indirect
relationships (does not require physical contact). The scores for
A), B), and C are 29, 24, and 16 respectively.
Found at: doi:10.1371/journal.pone.0007916.s004 (0.48 MB
PDF)
Figure S5 Plasma levels of 25 proteins stratified by population
and surgical status. Dotted lines connect surgical and pre-surgical
protein levels measured within the same women under both
surgical and non-surgical conditions.
Found at: doi:10.1371/journal.pone.0007916.s005 (0.28 MB
PDF)
Table S1 Summary of all proteins identified in mouse plasma.
Found at: doi:10.1371/journal.pone.0007916.s006 (0.46 MB
XLS)
Table S2 Proteins increased at least 1.5-fold in plasma taken
from K-ras/Pten mice compared to controls, appended with
ovarian cancer cell-derived proteins assayed in human plasma. P-
value for all mouse plasma ratios ,0.05. The table summarizes
fold difference for each protein. In addition, the ratios of secreted
protein/total extract and surface protein/total extract in human
ascites derived tumor cells/cancer cell lines [15] are shown for
comparison for each upregulated protein in murine plasma.
*Indicates cancer-only peptide(s) also observed. ELISA p-values
and coefficients from logistic regression for proteins assayed in
human plasma are summarized.
Found at: doi:10.1371/journal.pone.0007916.s007 (0.06 MB
XLS)
Table S3 Proteins decreased at least 1.5-fold in plasma taken
from K-ras/Pten mice compared to controls. P-value for all mouse
plasma ratios ,0.05.
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PLoS ONE | www.plosone.org 11 November 2009 | Volume 4 | Issue 11 | e7916Found at: doi:10.1371/journal.pone.0007916.s008 (0.02 MB
XLS)
Table S4 Detailed information about the 58 proteins found up-
regulated in the mouse model plasma experiment and enriched in
the human cancer cell data.
Found at: doi:10.1371/journal.pone.0007916.s009 (0.04 MB
XLS)
Table S5 Categorization of upregulated IPAS data into cancer
related biological processes. Each upregulated protein was
assigned to a cancer related process according to its ranked
network appearance determined by Ingenuity Pathway Analysis.
Found at: doi:10.1371/journal.pone.0007916.s010 (0.04 MB
XLS)
Table S6 Detailed GO processes for GeneGo networks shown in
Figure S2.
Found at: doi:10.1371/journal.pone.0007916.s011 (0.03 MB
XLS)
Table S7 Clinical characteristics and protein level measure-
ments for individual human samples.
Found at: doi:10.1371/journal.pone.0007916.s012 (0.11 MB
XLS)
Table S8 Summary statistics for the Generalized Estimating
Equations (GEE) methods to adjust for surgical collection
conditions.
Found at: doi:10.1371/journal.pone.0007916.s013 (0.02 MB
XLS)
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